IL-15 (mutant) (human):Fc (mouse) (rec.) (Biotin)
The extracellular domain of human IL-15 (aa 49-162) including mutations at Q149D and Q156D is fused to the N-terminus of the Fc region of mouse IgG2a.
This mutant IL-15/Fc fusion protein specifically binds to the IL-15R, competitively inhibits IL-15-triggered cell proliferation, promotes transplant tolerance, does not activate the STAT-signaling pathway, and exerts a prolonged circulating half-life caused by the modified Fc domain.
|Endotoxin Content||<0.06EU/μg protein (LAL test; Lonza).|
|Formulation||Lyophilized. In PBS and 0.09% sodium azide.|
|Protein Negative Control|
|Other Product Data||
NCBI reference NP_751914.1: IL-15 (human). The vial contains 20µg.
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Avoid freeze/thaw cycles.|
|Use/Stability||Stable for at least 6 months after receipt when stored at +4°C.|
|Product Specification Sheet|
Interleukin-15 (IL-15) has a broad spectrum of biological activities. It is crucial for the development, proliferation, survival and differentiation of multiple cells from both innate and adaptive immune systems. IL-15 up-regulation has a central role in the development of several autoimmune or chronic inflammatory disorders. Targeting IL-15 or its receptor may have a valuable impact on the treatment of immune-mediated diseases. IL-15 participates in the development of important immune antitumor mechanisms. It activates CD8(+) T cells, natural killer (NK) cells, NK T cells, and can promote the formation of antitumor antibodies. IL-15 can also protect T effector cells from the action of T regulatory cells and reverse tolerance to tumor-associated antigens. In pre-clinical studies IL-15 has been found to demonstrate potentiated antitumor effects following pre-association with IL-15Rα, or when used in combination with chemotherapy, adoptive therapy, monoclonal antibodies, and tumor vaccines.
Application: Useful for immunofluorescent staining and flow cytometric analysis to identify and enumerate IL-15Rα expressing cells within mixed cell populations.
- Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity: Y.S. Kim, et al.; J. Immunol. 160, 5742 (1998)
- An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection: S. Ferrari-Lacraz, et al.; J. Immunol. 167, 3478 (2001)
- Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance: X.X. Zheng, et al.; Immunity 19, 503 (2003)
- Limiting γc expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors: C.M. Smyth, et al.; Blood 110, 91 (2007)